BioMark Diagnostics (BUX) AI Stock Analysis

• Market Cap: C$37.31M
• Dividend Yield: N/A
• Average Volume (3M): 25.40K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.31
• Revenue Growth: -5.52%
• EPS Growth: -24.10%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 50
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 105,090,210
• 10 Day Avg. Volume: 24,924
• 30 Day Avg. Volume: 25,404
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.50
• Price Target Upside: 35.14% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 61 Neutral
• Price Target: C$0.50 ▲(35.14% Upside)

BioMark Diagnostics' overall stock score is driven by positive technical momentum and strategic corporate events, despite financial challenges and valuation concerns. The company's strategic initiatives and market expansion efforts are key strengths, while financial performance remains a significant risk.

BioMark Diagnostics Business Overview & Revenue Model

Company Description

BioMark Diagnostics (BUX) is a biotechnology company specializing in the development of innovative diagnostic tools and solutions for cancer detection and monitoring. The company focuses on the identification of biomarkers that enable early diagnosis and treatment options, primarily targeting sectors such as oncology and personalized medicine. BioMark's core products include non-invasive tests that utilize advanced molecular biology techniques to provide accurate and timely results for patients and healthcare providers.

How the Company Makes Money

BioMark Diagnostics generates revenue through the sale of its diagnostic testing services and products, which are aimed at healthcare providers, hospitals, and laboratories. The company charges fees for each test conducted, with pricing structures that may vary based on test complexity and volume. Additionally, BioMark may engage in partnerships with pharmaceutical companies and research institutions for collaborative projects, which can bring in revenue through licensing agreements and research funding. The company also potentially benefits from grants and investments aimed at advancing its technology and expanding its market reach.

BioMark Diagnostics Financial Statement Overview

Summary

BioMark Diagnostics faces significant financial challenges with negative profitability, high leverage, and negative cash flows. The company shows a weak financial position with a critical need to stabilize revenue and improve operational efficiencies. The negative equity and consistent losses highlight the urgency for strategic financial restructuring.

Income Statement

BioMark Diagnostics shows negative profitability with consistent net losses over the periods analyzed. The gross profit margin and net profit margin are both negative, indicating operating challenges. Revenue growth is also inconsistent, with fluctuations and a recent decline in TTM. Margins for EBIT and EBITDA are deeply negative, reflecting operational inefficiencies.

Balance Sheet

The company's balance sheet reveals high financial leverage with a negative stockholders' equity, indicating potential solvency concerns. The debt-to-equity ratio is not calculable due to negative equity, and ROE is also negative, highlighting the lack of returns for shareholders. The equity ratio is negative, reinforcing the fragile financial positioning.

Cash Flow

Cash flow analysis shows negative free cash flow, indicating potential liquidity challenges. Operating cash flow remains negative, and the ratios of operating and free cash flow to net income are not favorable. Although financing activities are providing some cash inflow, it is not sufficient to cover operational cash outflows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	154.22K	154.22K	163.22K	153.49K	43.93K	0.00
Gross Profit	96.46K	154.22K	163.22K	-232.70K	43.93K	-13.69K
EBITDA	-1.46M	-1.46M	-919.05K	-1.35M	-1.22M	-1.08M
Net Income	-1.93M	-1.93M	-1.43M	-1.84M	-1.45M	-1.09M
Balance Sheet
Total Assets	3.13M	3.13M	1.09M	732.29K	1.47M	952.94K
Cash, Cash Equivalents and Short-Term Investments	2.48M	2.48M	156.75K	72.04K	382.71K	877.68K
Total Debt	454.16K	454.16K	805.93K	823.87K	1.05M	119.32K
Total Liabilities	1.39M	1.39M	1.70M	1.88M	2.11M	1.03M
Stockholders Equity	1.74M	1.74M	-609.61K	-1.15M	-635.69K	-79.09K
Cash Flow
Free Cash Flow	-1.10M	-1.10M	-986.91K	-919.72K	-1.26M	-455.55K
Operating Cash Flow	-1.09M	-1.09M	-982.52K	-914.42K	-1.20M	-455.55K
Investing Cash Flow	-3.53K	-3.53K	-4.39K	-5.30K	-59.20K	-3.20K
Financing Cash Flow	3.42M	3.42M	1.07M	609.05K	768.16K	724.63K

BioMark Diagnostics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.37
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BUX, the sentiment is Positive. The current price of 0.37 is above the 20-day moving average (MA) of 0.35, above the 50-day MA of 0.34, and above the 200-day MA of 0.26, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.32 is Neutral, neither overbought nor oversold. The STOCH value of 79.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BUX.

BioMark Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BUX	61 Neutral	C$37.31M	―	-340.71%	―	-5.52%	-24.10%
ADK	52 Neutral	C$27.50M	―	366.78%	―	-39.00%	-11.21%
Sector *	46 Neutral	C$218.42M	-0.38	-24.34%	3.17%	19.38%	-2.35%
SONA	40 Underperform	C$57.43M	―	-390.46%	―	―	14.29%
TELO	28 Underperform	C$7.50M	―	-303.19%	―	―	23.32%

BioMark Diagnostics Corporate Events

BioMark Diagnostics Expands into North Africa with Strategic Partnership

BioMark Diagnostics has announced a strategic partnership with SAMA CONSULTING SARL to introduce its liquid biopsy platform for lung cancer detection in Tunisia and potentially expand across North Africa. This collaboration aims to address the high mortality rate from lung cancer in the region by using BioMark’s advanced technology, starting with a proof-of-concept trial in October 2025. The partnership signifies BioMark’s strategic entry into the North African market, leveraging SAMA’s local expertise to facilitate rapid implementation and regulatory compliance, with potential expansion to other countries in the region.

BioMark Diagnostics Expands Laboratory Services to Boost Lung Cancer Assay Commercialization

BioMark Diagnostics Inc. has announced the expansion of its specialty laboratory services in Quebec, which includes the acquisition of advanced equipment that doubles its testing capacity. This strategic move is set to accelerate the commercialization of its metabolomic-based lung cancer diagnostic assay, addressing the increasing global demand for non-invasive liquid biopsy diagnostics. The expansion positions BioMark as a central hub for innovation and high-throughput diagnostics, facilitating international partnerships and enhancing research capabilities. This development supports BioMark’s vision of scalable growth, enabling broader deployment strategies through clinical partnerships and expanding its contract research programs, ultimately enhancing long-term shareholder value.

BioMark Diagnostics Announces 2025 Achievements and Strategic Milestones for 2025-2026

BioMark Diagnostics Inc. announced its fiscal year 2025 achievements and strategic milestones for 2025-2026, showcasing resilience in a challenging funding environment for biotechnology firms. The company secured CAD $4.26 million through a private placement, maintained investor confidence, and achieved significant progress across its strategic pillars, including financial strength, operational advancements, lab certification, and strategic collaborations. Key milestones for the upcoming year include expanding laboratory capacity, completing a pivotal lung cancer clinical trial, and launching commercial operations for its lung cancer assay in Quebec, with plans to secure CLIA certification for U.S. market entry by early 2026.

BioMark Diagnostics Unveils AI Breakthrough in Early Lung Cancer Detection

BioMark Diagnostics has announced a breakthrough in AI-powered metabolomics for oncology with the publication of a study on a novel graph neural network (GNN) model. This model, known as M-GNN, significantly enhances early lung cancer detection by analyzing complex biological interactions, marking a pivotal advancement in the field. The research, conducted in collaboration with Harrisburg University and St. Boniface Hospital, highlights BioMark’s commitment to AI-driven diagnostics and positions the company at the forefront of precision oncology. While promising, further validation on diverse datasets is needed for clinical application, but the technology holds potential for expanding into treatment response monitoring and new therapeutic target discovery.

BioMark Diagnostics Validates High Accuracy of Early-Stage Lung Cancer Test

BioMark Diagnostics has announced a significant publication in the International Journal of Molecular Sciences, validating the high specificity and accuracy of its early-stage lung cancer test. The study, which included a large and diverse patient cohort, demonstrated the test’s ability to distinguish early-stage non-small cell lung cancer from other non-cancerous lung diseases, achieving over 93% AUROC values. This milestone enhances BioMark’s positioning in the oncology diagnostics industry, offering a promising alternative to current screening methods and potentially improving patient outcomes through earlier interventions.